Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7246 to 7260 of 8314 results

  1. Smoking: supporting people to stop (QS43)

    This quality standard has been updated and replaced by NICE quality standard 207.

  2. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

  3. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

    This evidence summary has been withdrawn because licensed products are now available.

  4. COVID-19 rapid guideline: severe asthma (NG166)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.

  5. COVID-19 rapid guideline: delivery of radiotherapy (NG162)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  6. COVID-19 rapid guideline: dialysis service delivery (NG160)

    May 2022: This guidance has been withdrawn. For the latest guidance, see the UK Kidney Association’s recommendations for minimising the risk of transmission of COVID-19 in adult haemodialysis units. See also NICE's guideline on managing COVID-19

  7. COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

    September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  8. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  9. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.

  10. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  11. COVID-19 rapid guideline: cystic fibrosis (NG170)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with cystic fibrosis see our guideline on diagnosing and managing cystic fibrosis and for people with COVID-19 see our guideline on managing COVID-19.

  12. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  13. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For children and young people with COVID-19 see our guideline on managing COVID-19

  14. COVID-19 rapid guideline: interstitial lung disease (NG177)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.